Oral tolerance for the treatment of autoimmune diseases - PubMed (original) (raw)
Review
Oral tolerance for the treatment of autoimmune diseases
H L Weiner. Annu Rev Med. 1997.
Abstract
Orally administered autoantigens suppress autoimmunity in animal models, including experimental allergic encephalomyelitis, collagen and adjuvant-induced arthritis, uveitis, and diabetes in the non-obese diabetic mouse. Low doses of oral antigen induce antigen-specific regulatory T-cells in the gut, which act by releasing inhibitory cytokines such as transforming growth factor-beta, interleukin-4, and interleukin-10 at the target organ. Thus, one can suppress inflammation at a target organ by orally administering an antigen derived from the site of inflammation, even if it is not the target of the autoimmune response. Initial human trials of orally administered antigen have shown positive findings in patients with multiple sclerosis and rheumatoid arthritis. A double-blind, placebo-controlled, phase III multi-center trial of oral myelin in 515 relapsing-remitting multiple sclerosis patients is in progress, as are phase II clinical trials investigating the oral administration of type II collagen in rheumatoid arthritis, S-antigen in uveitis, and insulin in type I diabetes.
Similar articles
- Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens.
Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Weiner HL, et al. Annu Rev Immunol. 1994;12:809-37. doi: 10.1146/annurev.iy.12.040194.004113. Annu Rev Immunol. 1994. PMID: 8011298 Review. - Oral tolerance: therapeutic implications for autoimmune diseases.
Faria AM, Weiner HL. Faria AM, et al. Clin Dev Immunol. 2006 Jun-Dec;13(2-4):143-57. doi: 10.1080/17402520600876804. Clin Dev Immunol. 2006. PMID: 17162357 Free PMC article. Review. - Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases.
Fowler E, Weiner HL. Fowler E, et al. Biopolymers. 1997;43(4):323-35. doi: 10.1002/(SICI)1097-0282(1997)43:4<323::AID-BIP5>3.0.CO;2-X. Biopolymers. 1997. PMID: 9316395 Review. - Oral tolerance in the control of experimental models of autoimmune disease.
Staines NA, Harper N. Staines NA, et al. Z Rheumatol. 1995 May-Jun;54(3):145-54. Z Rheumatol. 1995. PMID: 7660685 Review.
Cited by
- Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.
Luo J, Kuryatov A, Lindstrom JM. Luo J, et al. Ann Neurol. 2010 Apr;67(4):441-51. doi: 10.1002/ana.21901. Ann Neurol. 2010. PMID: 20437579 Free PMC article. - Effects of overexpression of IL-10, IL-12, TGF-beta and IL-4 on allergen induced change in bronchial responsiveness.
Fu CL, Ye YL, Lee YL, Chiang BL. Fu CL, et al. Respir Res. 2006 May 8;7(1):72. doi: 10.1186/1465-9921-7-72. Respir Res. 2006. PMID: 16677403 Free PMC article. - LAP+CD4+ T cells are elevated among the peripheral blood mononuclear cells and tumor tissue of patients with hepatocellular carcinoma.
Ou X, Guan J, Chen JS, Ying JC, Liu XP, Tian PK, Liu JK, Nie LP, Zhao Y, Yu GY. Ou X, et al. Exp Ther Med. 2018 Aug;16(2):788-796. doi: 10.3892/etm.2018.6229. Epub 2018 May 29. Exp Ther Med. 2018. PMID: 30116333 Free PMC article. - Oral Tolerance Induced by OVA Intake Ameliorates TNBS-Induced Colitis in Mice.
Paiatto LN, Silva FG, Bier J, Brochetto-Braga MR, Yamada ÁT, Tamashiro WM, Simioni PU. Paiatto LN, et al. PLoS One. 2017 Jan 18;12(1):e0170205. doi: 10.1371/journal.pone.0170205. eCollection 2017. PLoS One. 2017. PMID: 28099498 Free PMC article. - Oral tolerance.
Strober W, Kelsall B, Marth T. Strober W, et al. J Clin Immunol. 1998 Jan;18(1):1-30. doi: 10.1023/a:1023222003039. J Clin Immunol. 1998. PMID: 9475350 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical